Febrile neutropenia in patients treated with chemotherapy/immune checkpoint inhibition: a MASCC consensus statement Authors: Tim Cooksley, Carme Font, Karin Thursky, Bernardo Rapoport, Claire Falandry, Florian Scotte Published: 2026 ABSTRACT Chemotherapy/immune checkpoint inhibitor (ICI) therapy is increasingly standard of care for a range of cancers. Increasing numbers of emergency cancer presentations mean alternative pathways are required to ensure sustainable services and improve outcomes. Febrile neutropenia (FN) is common in patients treated with chemotherapy/ICI therapy. Risk stratifying patients with FN is essential to personalise acute management and optimise use of healthcare resources. Management of patients with low-risk FN in an outpatient setting is proven to be safe and effective. The MASCC score is well validated for risk stratification in FN, and patients with a score ≥ 21 are likely to be suitable for outpatient management. It has not been validated in patients treated with combined chemotherapy/ICI regimens. This MASCC position paper outlines an approach for acute ambulatory management of low-risk FN in this cohort and produces ten position points. A literature search was performed up to the 31st May 2025 for outpatient management of FN in patients treated with chemotherapy/ICI therapy. Only one paper met the criteria highlighting the need for prospective and real-world data. Patients treated with a MASCC score < 21 are high risk and require standard neutropenic sepsis management. Empirical usage of high-dose steroids in patients presenting with FN on chemo/ICI therapy with grade ≥ 3 diarrhoea and/or transaminitis is not recommended. Patients treated with chemotherapy/ICI therapy with low-risk FN should be treated on the same pathway as those treated with chemotherapy alone with inclusion criteria adapted to recognise their eligibility. ICI-mediated neutropenia should be considered in patients receiving combined chemotherapy/ICI therapy when the timing of presentation is unanticipated or there is a failure of neutrophil recovery with persistent grade 3/4 neutropenia 10 days following administration. Initial treatment of suspected ICI-mediated neutropenia is to commence high-dose steroids and consider short-acting G-CSF. Introduction Combined chemotherapy/immune checkpoint inhibitor (ICI) therapy is increasingly the standard of care for a range of cancers including small cell and non-small cell lung cancer, upper gastrointestinal cancer, cholangiocarcinoma, cervical cancer, and triple-negative breast cancer in both the neoadjuvant and metastatic setting. [1–6] Side effects of these regimens include both additive and synergistic toxicities from chemotherapy and ICI as well as immune-related adverse events. This results in an increased number of emergency presentations. This position paper considers the challenges of managing patients with febrile neutropenia treated with combined chemotherapy/ICI therapy. The large number of patients treated with this therapy necessitates guidance to support their management. It considers the suitability of managing patients with potentially low-risk febrile neutropenia treated with these regimens in an ambulatory emergency setting or other non-hospital-based acute settings. The ten position points are reached by expert opinion consensus (see Table 1) supported by a literature search conducted by a specialist external agency (see Appendix). The grade of recommendation for each position point was assessed using the standard A–D scoring system [7]. Table 1MASCC position points relating to the management of febrile neutropenia in patients treated with chemotherapy/immune checkpoint inhibition1. Increasing numbers of emergency presentations in cancer patients means alternative pathways, such as outpatient ambulatory emergency care, are required to ensure sustainable services and improve outcomes2. Risk stratifying patients with febrile neutropenia as high or low risk is essential to personalise acute management and optimise use of healthcare resources3. The MASCC score is a well-validated score for risk stratification in febrile neutropenia and patients with a score ≥ 21 are likely to be suitable for outpatient or ambulatory emergency care4. There is a lack of prospective and real-world data in the management of toxicities from newer regimens, such as combined chemotherapy/immune checkpoint inhibition5. Patients treated with chemotherapy/ICI presenting with febrile neutropenia and a MASCC risk index < 21 are high risk and require standard neutropenic sepsis management6. Patients treated with chemotherapy/ICI therapy with low-risk febrile neutropenia should be treated on the same pathway as those treated with chemotherapy alone with inclusion criteria adapted to recognise their eligibility if required7. Empirical usage of high-dose steroids in patients presenting with febrile neutropenia on chemo/ICI therapy with grade ≥ 3 diarrhoea and/or transaminitis should be carefully balanced against the severity of sepsis, need of investigation for infective pathogens and clinical suspicion that presentation is ICI mediated8. ICI-mediated neutropenia should be considered in patients receiving combined chemotherapy/ICI therapy when the timing of presentation is unanticipated or there is a failure of neutrophil recovery with persistent grade 3/4 neutropenia 10 days following administration9. Initial treatment of suspected ICI-mediated neutropenia is to commence high-dose steroids (for example, 1 mg/kg oral prednisolone) and consider short-acting G-CSF10. Telemedicine and provision of remote monitoring using patient-reported outcome measures are increasingly important adjuncts to acute ambulatory cancer management programmes, such as low-risk febrile neutropenia Table 1MASCC position points relating to the management of febrile neutropenia in patients treated with chemotherapy/immune checkpoint inhibition1. Increasing numbers of emergency presentations in cancer patients means alternative pathways, such as outpatient ambulatory emergency care, are required to ensure sustainable services and improve outcomes2. Risk stratifying patients with febrile neutropenia as high or low risk is essential to personalise acute management and optimise use of healthcare resources3. The MASCC score is a well-validated score for risk stratification in febrile neutropenia and patients with a score ≥ 21 are likely to be suitable for outpatient or ambulatory emergency care4. There is a lack of prospective and real-world data in the management of toxicities from newer regimens, such as combined chemotherapy/immune checkpoint inhibition5. Patients treated with chemotherapy/ICI presenting with febrile neutropenia and a MASCC risk index < 21 are high risk and require standard neutropenic sepsis management6. Patients treated with chemotherapy/ICI therapy with low-risk febrile neutropenia should be treated on the same pathway as those treated with chemotherapy alone with inclusion criteria adapted to recognise their eligibility if required7. Empirical usage of high-dose steroids in patients presenting with febrile neutropenia on chemo/ICI therapy with grade ≥ 3 diarrhoea and/or transaminitis should be carefully balanced against the severity of sepsis, need of investigation for infective pathogens and clinical suspicion that presentation is ICI mediated8. ICI-mediated neutropenia should be considered in patients receiving combined chemotherapy/ICI therapy when the timing of presentation is unanticipated or there is a failure of neutrophil recovery with persistent grade 3/4 neutropenia 10 days following administration9. Initial treatment of suspected ICI-mediated neutropenia is to commence high-dose steroids (for example, 1 mg/kg oral prednisolone) and consider short-acting G-CSF10. Telemedicine and provision of remote monitoring using patient-reported outcome measures are increasingly important adjuncts to acute ambulatory cancer management programmes, such as low-risk febrile neutropenia MASCC position points relating to the management of febrile neutropenia in patients treated with chemotherapy/immune checkpoint inhibition Position point 1: Increasing numbers of emergency presentations in cancer patients means alternative pathways, such as outpatient ambulatory emergency care, are required to ensure sustainable services and improve outcomes—A Cancer care has become increasingly specialised, with most patients receiving treatment in outpatient settings. While this reflects significant progress, it has also contributed to a notable rise in cancer-related emergencies, as more patients undergo complex therapies, such as chemotherapy/ICI therapy [8–12]. In the USA, approximately 4.5 million emergency department (ED) visits annually involve adults with cancer [13]. Compared with other ED patients, those with cancer are older, more likely to arrive by ambulance services, and experience longer lengths of stay in the ED [14]. The increased pressures internationally on emergency services have driven the need to manage more patients in non-inpatient settings through emergency ambulatory care or hospital at home innovations [15, 16 ]. This reduces pressures on inpatient hospital services, may improve patient satisfaction, reduces nosocomial infections and other hospital-related complications, reduces financial toxicity, facilitates patient flow, and aims to reduce the pressures and risks of ED overcrowding [17, 18 ]. This approach is essential to maintain sustainable emergency oncology services. Position point 2: Risk stratifying patients with febrile neutropenia as high or low risk is essential to personalise acute management and optimise use of healthcare resources—B Febrile neutropenia is a common emergency presentation in patients treated with chemotherapy/ICI therapy [19, 20]. Most remains driven in a probabilistic, cumulative, and dose-dependent manner in response to chemotherapy, but it can also be due to a rare and stochastic, immune-related event. Patients with febrile neutropenia are a heterogeneous group with only a minority developing significant medical and potentially life-threatening complications [21, 22]. Assessing and identifying whether patients with febrile neutropenia are at high or low risk for the development of severe infection and significant medical complications is important in order to tailor the clinical management and optimise use of healthcare resources in each setting [23]. Variables used to do this include the presenting clinical condition at febrile neutropenia diagnosis, the underlying malignancy, and pre-existing medical co-morbidities [24, 25]. Position point 3: The MASCC score is a well-validated score for risk stratification in febrile neutropenia and patients with a score ≥ 21 are likely to be suitable for outpatient or ambulatory emergency care—A Management of patients with low-risk febrile neutropenia in an outpatient/acute ambulatory setting is proven to be safe and effective [21–25]. MASCC has pioneered work in this field and developed a risk-assessment model that includes seven independent prognostic variables, each with an assigned integer value [26, 27]. A MASCC risk index of ≥ 21 identifies low-risk patients with a positive predictive value of 91% of developing serious complications [21, 25]. Patients with a MASCC score ≥ 21 should be considered for outpatient/acute ambulatory management (see Fig. 1). Risk scores should be used in conjunction with clinical judgement and safety net criteria, including carer support and distance to hospital, for the identification of patients suitable for acute outpatient management of febrile neutropenia [28]. The MASCC score has been prospectively validated in several settings, and its use is broadly recommended as a simple strategy to apply as a triaging tool. The MASCC score has not yet been validated in patients treated with combined chemotherapy/ICI regimens.Fig. 1Utilising acute ambulatory management in patients with low-risk febrile neutropenia undergoing chemotherapy/ICI treatment Utilising acute ambulatory management in patients with low-risk febrile neutropenia undergoing chemotherapy/ICI treatment There is significant heterogeneity in the modelling of outpatient low-risk febrile neutropenia management reflecting the variation in pathways for the delivery of emergency oncology care and the spectrum of clinical and psychosocial presentations [18]. The majority of real-world data is reported from acute care in specialist cancer centres [29–31], some through collaborations between emergency clinicians and oncologists [32] with advanced care practitioners being pivotal to their implementation in many models [30–32]. This also reflects differing pathways for early outpatient management with some centres discharging patients within 4 h of acute presentation whilst other units utilise early discharge after 12 h of monitoring in areas, such as ED observation units. The COVID19 pandemic has in many ways highlighted the importance of ensuring that patients with low-risk febrile neutropenia are managed in ambulatory settings [33]. There are significant challenges in delivering acute ambulatory management for patients with low-risk febrile neutropenia. One study reported that only 30% of patients suitable for ambulatory management received it due to logistical challenges such as care packages, transport issues, and, in a small number of cases, patient refusal to be discharged [34]. Increasingly, levels of patient digital and language literacy are barriers to the ability to manage their care in an emergency ambulatory setting. Variation in international emergency oncology care delivery necessitates local adaptation and modelling of low-risk febrile neutropenia pathways. Low-resource setting areas often do not have the infrastructure to rapidly implement and support emergency ambulatory models. However, the fundamentals of ambulatory febrile neutropenia management—appropriate antibiotic therapy, patient education, and clear guidance on where to represent if becoming unwell—are achievable in low-resource settings. Acute ambulatory management of low-risk febrile neutropenia delivers significant cost savings and improves patient experience and satisfaction [29, 35]. A cost analysis of an ambulatory low-risk febrile neutropenia service managing 25 patients in a 1-year period calculated cost savings of $AUD71895 [29]. A Canadian survey showed that 75% of cancer patients preferred outpatient antibiotic therapy [36]. Implementation and governance of services are usually supported by extension of existing emergency oncology services and performed alongside other ambulatory pathways due to the relatively small number of patients at each cancer centre. A fundamental element of all outpatient febrile neutropenia pathways is good continuity of care and communication between the emergency and treating oncology teams. Position point 4: There is a lack of prospective and real-world data in the management of toxicities from newer regimens, such as combined chemotherapy/immune checkpoint inhibition—D A meta-analysis of 29 studies evaluating the risk of grade I–IV neutropenia of systemic chemotherapy ± ICI found the addition of ICI to chemotherapy increased the risk by 10% (odds ratio 1.1; 95% CI [1.01–1.19] [37]. No differences were found between the type of ICI therapy and the primary tumour site [37]. A literature search was performed using MEDLINE (PubMed), ASCO, ESMO, and MASCC abstracts databases up to the 31 st of May 2025 relating to emergency ambulatory management of febrile neutropenia in patients treated with chemotherapy/ICI therapy. Only one paper met the inclusion criteria of both searches in a cohort of breast patients being treated in the neoadjuvant setting [38]. This paper suggested triple-negative breast cancer patients receiving neoadjuvant pembrolizumab in addition to carboplatin/paclitaxel followed by epirubicin/cyclophosphamide (PC-EC) could have more severe presentations with febrile neutropenia, illustrated by lower MASCC scores and more abnormal vital signs at presentation [38]. Patients with a MASCC ≥ 21 were managed on an acute ambulatory outpatient basis. This highlights a lack of real-world data and research into newer systemic anti-cancer therapy regimens associated with febrile neutropenia. A prospective multinational database of patients presenting with febrile neutropenia treated with chemotherapy/ICI would be valuable both to validate the MASCC risk index and to gain further insights into its optimal management. Specifically determining risk factors for, and indicators of, ICI-related neutropenia would be invaluable. Position point 5: Patients treated with chemotherapy/ICI presenting with febrile neutropenia and a MASCC risk index < 21 are high risk and require standard neutropenic sepsis management—A Patients treated with chemotherapy/ICI presenting with febrile neutropenia and a MASCC risk index < 21 are high risk and require standard neutropenic sepsis management. These patients require prompt administration of broad-spectrum intravenous antimicrobials, careful workup for, and management of, any source of infection, and comprehensive supportive therapy with a low threshold for escalation to critical care for support if signs of septic shock [39, 40]. Physiological doses of steroids to support sepsis management should be administered as many patients have received steroids as anti-emetic prophylaxis [41] and have a risk of adrenal insufficiency due to ICI therapy which is difficult to diagnose during an acute septic episode [42]. Position point 6: Patients treated with chemotherapy/ICI therapy with low-risk febrile neutropenia should be treated on the same pathway as those treated with chemotherapy alone with inclusion criteria adapted to recognise their eligibility if required—C Patients treated with chemotherapy/ICI therapy with low-risk febrile neutropenia should be treated on the same pathway as those treated with chemotherapy, with inclusion criteria adapted to recognise their eligibility if required. There are guideline and national exemplar pathways to support local implementation [33, 43, 44]. The core of each of these pathways is broad-spectrum oral antimicrobial therapy [34, 45], clear patient and caregiver advice as to signs and symptoms that require further urgent assessment and where they should attend, supportive therapies, and a clinical review within 72 h to ensure good clinical progress. Increased utilisation of remote monitoring systems should increasingly be incorporated into these pathways to increase their safety and widen the access of patients suitable for outpatient management. Prior to ambulatory management of febrile neutropenia in this cohort, thorough and detailed assessment of other potential concomitant ICI-related toxicities must be undertaken. Position point 7: Empirical usage of high-dose steroids in patients presenting with febrile neutropenia on chemo/ICI therapy with grade ≥ 3 diarrhoea and/or transaminitis should be carefully balanced against the severity of sepsis, need of investigation for infective pathogens and clinical suspicion that presentation is ICI mediated—C Many patients presenting with febrile neutropenia will have grade ≥ 3 diarrhoea and/or transaminitis. In this clinical context, these are more likely to be driven by chemotherapy and a septic state rather than due to ICI-related toxicity, although it is often difficult to differentiate on initial assessment [46]. Empirical usage of high-dose steroids for potential ICI-related colitis or hepatitis is not recommended in this scenario, but should symptoms persist following febrile neutropenia management or there is significant clinical concern of an ICI-related element, later treatment may be required. Immune-related toxicities should be managed in accordance with standard international guidance such as the MASCC recommendations [47]. Concomitant presentations with suspected severe ICI-mediated organ toxicity may require inpatient management precluding ambulatory care. ICI-mediated hypothalamic–pituitary–adrenal axis toxicity cannot be reliably assessed biochemically in patients with recent exogenous steroid usage as part of their post-chemotherapy anti-emetic regimen. Position point 8: ICI-mediated neutropenia should be considered in patients receiving combined chemotherapy/ICI therapy when the timing of presentation is unanticipated or there is a failure of neutrophil recovery with persistent grade 3/4 neutropenia 10 days following administration—C ICI-related neutropenia is a rare adverse event [48, 49]. Its incidence is < 1% with a median onset time of 3 cycles [48]. Although rare, ICI-related neutropenia is often severe. Data from a French pharmacovigilance study showed that at presentation, > 60% had grade 4 neutropenia and > 60% presented with febrile neutropenia [50]. Early recognition of ICI-related neutropenia in patients treated with chemotherapy/ICI therapy is challenging as the vast majority is driven by chemotherapy. Timing of the neutropenia is an important factor in aiding early recognition of a possible ICI-related neutropenia. For example, grade 4 neutropenia during weekly carboplatin/paclitaxel during PC-EC/Pembrolizumab. ICI-related neutropenia should be considered in patients receiving combined chemotherapy/ICI therapy when the timing of presentation is unanticipated or there is a failure of neutrophil recovery with persistent grade 3/4 neutropenia 10 days following administration. The clinical workup for suspected ICI-related neutropenia includes haematinics, ferritin, neutrophil antibodies, and a bone marrow aspirate [48]. Position point 9: Initial treatment of suspected ICI-mediated neutropenia is to commence high-dose steroids (for example, 1 mg/kg oral prednisolone) and consider short-acting G-CSF—C Initial treatment of ICI-related neutropenia is to commence high-dose steroids (for example, 1 mg/kg oral prednisolone) and short-acting G-CSF. If there is no response to initial therapy, further management is supported by bone marrow biopsy results. High-dose IV immunoglobulins should be administered to those with normal or hypercellular bone marrow in keeping with peripheral autoantibody-mediated immune destruction. Cyclosporine should be used for patients with hypoplastic or maturation-arrested bone marrow driven by CD8+ T-lymphocyte–mediated myeloid precursor destruction or suppression [48]. ICI-related neutropenia is often transient with most patients recovering within 1 month [51]. Careful monitoring for infective symptoms and withholding further chemotherapy are essential during the management of ICI-related neutropenia. Once neutrophils have recovered, rechallenge with ICI therapy can be considered [48]. Position point 10: Telemedicine and provision of remote monitoring using patient-reported outcome measures are increasingly important adjuncts to acute ambulatory cancer management programmes, such as low-risk febrile neutropenia—C Telemedicine and provision of remote monitoring using patient-reported outcome measures are increasingly important adjuncts to acute ambulatory cancer management programmes, such as low-risk febrile neutropenia [52, 53 ]. These will facilitate increased usage of acute ambulatory approaches with the ability to anticipate adverse consequences through clinical and biological monitoring [54]. This will be essential in future modelling services for emergency oncology, with the predictable growth in presentations being unsustainable for the current provision in most settings.